Evaluation of the quality of life and sexual functioning of women using a 30-μg ethinyloestradiol and 3-mg drospirenone combined oral contraceptive

References

• Rekomendacje Polskiego Towarzystwa Ginekologicznego dotyczące antykoncepcji hormonalnej—stan na rok 2006. Rekomendacje Polskiego Towarzystwa Ginekologicznego. Wydanie specjalne. [Polish Gynaecology Society's Recommendations on Hormonal Contraception—2006. Polish Gynaecology Society's Recommendations. Special Issue]. Ginekologia po Dyplomie 2006; 27–31
   Google Scholar
• Yuzpe A A. Oral contraception: trends over time. J Reprod Med 2002; 47: 967–973
   PubMed Web of Science ®Google Scholar
• Somma M A. Ethinyl estradiol/drospirenone (Yasmin): A newer oral contraceptive. Am Fam Physician 2004; 69: 24–25
   Google Scholar
• Keam S J, Wagstaff A J. Ethinylestradiol/drospirenone: A review of its use as an oral contraceptive. Treat Endocrinol 2003; 2: 49–70
   PubMedGoogle Scholar
• Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30 μg and drospirenone 3 mg (Yasmin) in clinical practice. Treat Endocrinol 2006; 5: 251–256
   PubMedGoogle Scholar
• Mansour D. Experiences with Yasmin: The acceptability of a novel oral contraceptive and its effect on well-being. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3)35–41
   PubMedGoogle Scholar
• Boschitsch E, Skarabis H, Wuttke W, et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. Eur J Contracept Reprod Health Care 2000; 5(Suppl 3)34–40
   PubMedGoogle Scholar
• Oelkers W. Drospirenone with combination with estrogens: For contraception and hormone replacement therapy. Climacteric 2005; 8(Suppl 3)19–27
   PubMedGoogle Scholar
• Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002; 7(Suppl 3)19–26
   PubMedGoogle Scholar
• Caruso S, Agnello C, Intelisano G, et al. Prospective study on sexual behavior of women using 30 μg ethinylestradiol and 3 mg drospirenone oral contraceptive. Contraception 2005; 72: 19–23
   PubMed Web of Science ®Google Scholar
• Ware J E, Snow K K, Kosinski M, et al. SF-36 Health Survey: Manual and interpretation guide. New England Medical Center, Health Institute, Boston 1993
   Google Scholar
• Ware J E, Kosinski M. SF-36 Physical and mental health summary scales: A manual for users of version 1, 2nd edn. Quality Metric Incorporated, Lincoln 2001
   Google Scholar
• Ware J E. SF-36 Health Survey update. Spine 2000; 25: 3130–3139
   PubMed Web of Science ®Google Scholar
• Ware J E, Kosinski M, Gandek B G, et al. The factor structure of the SF-36 health survey in 10 countries: Results from the International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol 1998; 51: 1159–1165
   PubMed Web of Science ®Google Scholar
• Turner-Bowker D M, Bartley P J, Ware J E. SF-36 Health Survey and ‘SF’ bibliography, 3rd edn. Quality Metric Incorporated, Lincoln 2002
   Google Scholar
• McHorney C A, Ware J E. Construction and validation of an alternate form general mental health scale for the Medical Outcomes Study Short Form 36-Item Health Survey. Med Care 1995; 33: 15–28
   PubMed Web of Science ®Google Scholar
• Jenkinson C. The SF-36 physical and mental health summary measures: An example of how to interpret scores. J Health Serv Res Policy 1998; 3: 92–96
   PubMedGoogle Scholar
• Rosen R, Brown C, Heinman J, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000; 26: 191–208
   PubMed Web of Science ®Google Scholar
• Meston C M. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003; 29: 39–46
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): Cross-validation and development of clinical cut-off scores. J Sex Marital Ther 2005; 31: 1–20
   PubMed Web of Science ®Google Scholar
• Lew-Starowicz Z. Skala SFŻ (Mell–Krat) – SFM. [SFŻ Scale (Mell–Krat) – SFM]. Seksuologia sądowa. [Forensic sexology], Z Lew-Starowicz. PZWL, Warszawa 2000; 380–387
   Google Scholar
• Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37–51
   PubMed Web of Science ®Google Scholar
• Bitzer J, Tschudin S, Meier-Burgoa J, et al. Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin). Schweiz Rundsch Med Prax 2003; 92: 1177–1184
   Google Scholar
• Mansour D. The non-contraceptive benefits and acceptability of Yasmin®. Eur J Contracept Reprod Health Care 2004; 9(Suppl 1)194
   PubMedGoogle Scholar
• Sillem M. Yasmin® and the extended regimen: current experience. Eur J Contracept Reprod Health Care 2004; 9(Suppl 1)194
   PubMedGoogle Scholar